Compare · LH vs RNLX
LH vs RNLX
Side-by-side comparison of Labcorp Holdings Inc. (LH) and Renalytix plc (RNLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LH and RNLX operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH carries a market cap of $30.24B.
- LH has hit the wire 11 times in the past 4 weeks while RNLX has been quiet.
- LH has more recent analyst coverage (25 ratings vs 4 for RNLX).
- Company
- Labcorp Holdings Inc.
- Renalytix plc
- Price
- -
- -
- Market cap
- $30.24B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 4
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Renalytix plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was founded in 2018 and is based in London, the United Kingdom.
Latest LH
- EVP, Pres of BLS, CMO & CSO Caveney Brian J sold $744,080 worth of shares (2,000 units at $372.04), decreasing direct ownership by 5% to 34,562 units (SEC Form 4)
- EVP and President, Diagnostics Vaughn Bryan T sold $108,232 worth of shares (306 units at $353.70) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 6,845 units (SEC Form 4)
- Labcorp Holdings Inc. upgraded by HSBC Securities with a new price target
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Speak at the UBS Global Healthcare Conference
- Director Parham Richelle P sold $389,395 worth of shares (1,078 units at $361.22), decreasing direct ownership by 32% to 2,288 units (SEC Form 4)
- EVP, CIO & CTO Oyegunwa Akinbolade converted options into 370 shares and covered exercise/tax liability with 118 shares, increasing direct ownership by 5% to 5,316 units (SEC Form 4) to satisfy tax liability
- EVP and President, Diagnostics Vaughn Bryan T converted options into 500 shares and covered exercise/tax liability with 194 shares, increasing direct ownership by 4% to 7,151 units (SEC Form 4) to cover taxes
- SEC Form 10-Q filed by Labcorp Holdings Inc.
- SEC Form 8-K filed by Labcorp Holdings Inc.
Latest RNLX
- SEC Form DEF 14A filed by Renalytix plc
- Commencement of trading on OTCQB in the United States
- Amendment: SEC Form SC 13D/A filed by Renalytix plc
- SEC Form PRE 14A filed by Renalytix plc
- Renalytix plc filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities
- SEC Form 10-K filed by Renalytix plc
- Renalytix plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Renalytix plc filed SEC Form 8-K: Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- HC Wainwright & Co. Reiterates Buy on Renalytix, Maintains $3 Price Target
- Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session